# THIRTEEN-YEAR PROSPECTIVE STUDY BETWEEN FISH CONSUMPTION, LONG-CHAIN N-3 FATTY ACIDS INTAKES AND COGNITIVE FUNCTION

# E. KESSE-GUYOT<sup>1,4</sup>, S. PÉNEAU<sup>2</sup>, M. FERRY<sup>1</sup>, C. JEANDEL<sup>2</sup>, S. HERCBERG<sup>1,3</sup>, P. GALAN<sup>1</sup> AND THE SU.VI.MAX 2 RESEARCH GROUP<sup>5</sup>

 INSERM U557; INRA U1125; CNAM; Paris 13. Human Nutrition Research Center of Ile de France, UFR SMBH Paris 13, SMBH, 74 rue Marcel Cachin, F-93017 Bobigny cedex, France; 2. Centre de Gérontologie Clinique Antonin Balmes, CHU Montpellier, Université I, France; 3. Département de Santé Publique, Hôpital Avicenne, Bobigny, F-93017, France.
Corresponding author: Dr. Emmanuelle Kesse-Guyot: INSERM U557; INRA U1125; CNAM; PARIS 13. Human Nutrition Research Center of Ile de France, UFR SMBH Paris 13, SMBH, 74 rue Marcel Cachin, F-93017 Bobigny cedex, France, Phone number: 00 33 1 48 38 89 79, Fax number: 00 33 1 48 38 89 31, E-mail: e.kesse@uren.smbh.univ-paris13.fr;
A full list of the SU.VI.MAX 2 Research Group Members is available in appendix 1

**Abstract:** *Objectives:* Because of their structural, anti-inflammatory and antithrombic properties, longchain n-3 fatty acids may be key factors in the aging process. We sought to elucidate the association between intake of long-chain n-3 fatty acids and/or fish and cognitive function evaluated 13 years after dietary assessment. *Design:* Prospective population-based study. *Participants/Setting:* 3,294 adults from the SU.VI.MAX study (Supplementation with Antioxidant Vitamins and Minerals study). *Measurements/Statistical analysis:* Subjects underwent a standardized clinical examination which included cognitive tests and self-reported cognitive difficulties scale (2007-2009). Poor scores were defined using percentiles as cut-off. Dietary data were assessed through repeated 24-h dietary records. Odd ratio (OR), comparing the fourth (Q4) to the first quartile (Q1), of having a poor score were calculated using adjusted logistic regression. *Results:* Self-reported cognitive difficulties were less frequent among subjects with higher intakes of total n-3 long chain fatty acids (OR = 0.72, CI 95%=0.56-0.92) and eicosapentaenoic acid (OR Q4 versus Q1 = 0.74, CI 95%=0.58-0.95), even after adjustment for depressive symptoms. A borderline significant association was also found with high fish consumption (OR Q4 versus Q1 = 0.80, CI 95%=0.63-1.01). *Conclusion:* Cognitive complaints, which may be an early indicator of cognitive decline, are less frequent among the elderly who have a high long-chain n-3 acids intake, as assessed 13 years earlier.

Key words: Cognition, cognitive difficulties, fish, omega-3 fatty acids.

### Introduction

In a context of increasing life span, it is of major public health importance to enhance the quality of aging, to optimize the health status of the elderly and to delay loss of autonomy. As modifiable factors, nutritional aspects are of particular interest as preventive goals.

In France, diet has been shown to be rich in n-6 fatty acids and poor in n-3 fatty acids (FA) (1). Nutritional guidelines have been recently developed to improve the health status of the general population via nutrition (2). In particular, these guidelines advise eating fish at least twice a week. It would be of major interest to estimate whether promoting long chain n-3 fatty acids, notably through fish consumption, can improve cognitive aging.

As essential structural components of the neuronal membrane, and through their anti-thrombotic and antiinflammatory properties (3), long-chain n-3 fatty acids are presumed to be key factors involved in the aging process, especially affecting cognitive functions (4).

However, observational epidemiologic studies evaluating the association between long-chain n-3 FA and/or fish and cognitive performance, cognitive decline and dementia, have produced inconsistent results according to recent reviews (5;6). Some studies suggested that long-chain n-3 FA intake and/or fish consumption may prevent dementia, and particularly Alzheimer diseases (7-10), while others did not (11, 12). Findings concerning cognitive performances (13-16) and

decline (17-20) are even more inconsistent.

Most studies focusing on aging and nutritional factors included older populations. Studies are lacking on the consequences of nutrition, as assessed during middle age, upon the quality of cognitive ageing.

The aim of the present study was to investigate the association between fish consumption, long-chain n-3 FA, in particular EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), and markers of cognitive function and subjective cognitive difficulties evaluated 13 years after dietary assessment, in men and women participating in the SU.VI.MAX 2 study.

# Materials and methods

# Population and data collection

# The SUVIMAX study

The SU.VIMAX study was initially a randomized doubleblind, placebo-controlled, primary prevention trial that began in 1994 and ended in 2002. Design and methods have been reported elsewhere (21, 22).

This study was initially designed to evaluate the effect of 8year daily antioxidant supplementation at nutritional doses (vitamin C, vitamin E, beta-carotene, selenium, zinc) on the incidence of cardiovascular disease and cancer. A total of 13,017 individuals (5,141 men aged 45–60 y and 7,876 women

# OMEGA-3 FATTY ACIDS, FISH AND COGNITION

aged 35–60 y) were included and followed for an average of 7.5 years. During that period, participants were invited to a yearly check-up consisting of blood sampling alternating with a clinical examination. Subjects were also invited to complete a 24 h record every 2 months for a total of 6 records per year covering all days of the week and all seasons. Data were collected through computerized questionnaires using the Minitel, a small terminal used in France as an adjunct to the telephone. Participants were assisted by an instruction manual for coding food portions including validated photographs of more than 250 foods represented in three different portion sizes. Subjects could also choose from two intermediate or two extreme portions, for a total of seven different possible portion sizes (23).

At baseline, data on gender, date of birth, smoking status, education level, physical activity and medication uses were collected by a self-administered questionnaire. Blood samples were obtained after a 12-h fast; all biochemical measurements were centralized in a single laboratory. Fasting blood glucose and total cholesterol were measured by using an enzymatic method (Advia 1650; Bayer Diagnostic, New York, NY). Blood pressure (BP) was measured using a standardized procedure with a mercury sphygmomanometer. It was taken twice from each arm in subjects who had been lying down for 10 min. The mean between the lowest right and left measures was retained.

### The SUVIMAX 2 study

In 2006, 8,330 SU.VI.MAX participants from among the 11,141 who ended the SU.VI.MAX trial accepted an invitation to undergo a new check-up in view of a future specific study. Among them, 7,180 subjects agreed to enroll in the SU.VI.MAX. 2 study. The aim of that study was to investigate the impact of nutrition on quality of aging.

All participants were invited to undergo a clinical examination in one of the medical centers participating in the study. Examination included a self-reported questionnaire completed by the participants and a clinical examination performed by trained technicians and geriatricians. The selfreported questionnaire included data on sociodemographic characteristics, lifestyle, personal medical history, family medical history, instrumental activities of daily living, depressive symptoms by means of a French version of the Center for Epidemiologic Studies Depression Scale (CES-D) (24) and self-reported memory complaint using McNair's Cognitive Difficulties Scale (CDS) (25).

The assessment of cognitive functions included a French version of the MMSE which evaluates overall cognitive functions (26), a 5-word test which is an immediate and delayed verbal memory test including free and cued recall (27).

In case of suspected health event (cardiovascular diseases and cancer), investigations were conducted to obtain relevant medical data (clinical, biochemical, histological, radiological reports) from participants, physicians and/or hospital. All reported cardio- and cerebrovascular events were reviewed and validated by an independent expert committee. The SU.VI.MAX and SU.VI.MAX 2 studies were approved by the Ethical Committee for Studies with Human Subjects of Paris-Cochin Hospital (CCPPRB  $n^{\circ}$  706 and  $n^{\circ}$  2364, respectively) and the Comité National Informatique et Liberté (CNIL  $n^{\circ}$  334641 and  $n^{\circ}$  907094, respectively).

# Inclusion criteria

Among the 7,180 potential participants, 6,850 subjects were able to come to the specific centers for the check-up. Among them, and for this specific analysis, we selected the 3,611 subjects who were older than 45 at baseline and who had completed at least six 24-h dietary records during the first two years of the SU.VI.MAX follow-up to better account for intra individual variability in intakes. In addition, a total of 317 subjects were excluded because of a missing value for at least one covariable (except for hypertension: a missing category was created because of more than 5% of missing value) (28), leaving 3,294 subjects for this specific analysis.

# Statistical analysis

Dietary nutrient intakes were calculated based on the average daily food intakes of each subject using a food composition table (29). Fish (and seafood) from composite dishes were taken into account for fish consumption estimation. N-3 long-chain FA intakes were calculated as the sum of EPA eicosapentaenoic acid), DHA (docosahexaenoic acid) and DPA (docosapentaenoic acid). Total n-3 FA intake was calculated as the sum of alphalinolenic acid and n-3 long-chain FA intake. Energy adjustment was performed using the residual method (30).

Scores for McNair CDS (range 0-148, lower is better) and MMSE (range 0-30, higher is better) were calculated. For the 5-word test, a weighted score was calculated as the sum of immediate and delayed recall (31, 32). Two points were attributed to immediate recall and one point to cued recall for a total of 20 points (higher is better).

For clinical cognitive assessment, poor score were identified according to the 10th percentile (15) of the test score (MMSE<27, 5-words test<18). For Mc Nair CDS, we used the 4th quartile as cut-off (CDS McNair>39).

Body mass index (BMI) was calculated by dividing weight by height-squared (kg/m<sup>2</sup>). Hypertension at baseline was defined as SBP>140 mmHg or a DBP> 90mmHg or reporting antihypertensive drugs use. Diabetes mellitus at baseline was defined as glycemia>7mmol/L or reporting oral hypoglycaemic agents use. Hypercholesterolemia was defined as serum totalcholestestol>6.5 mmol/L or reporting lipid lowering drugs use.

Interaction between gender and nutritional factors on outcome were tested.

Descriptive results are reported as percentage or mean  $\pm$  standard deviation, as appropriate. Differences between men and women were tested using the chi-square test or Wilcoxon-Mann-Whitney test, as appropriate.

Logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI 95%) of having a poor score

# JNHA: CLINICAL NEUROSCIENCES

on one of the test score according to the gender-specific quartile of fish consumption or of fatty acid intake. Tests for linear trend were performed using the ordinal score.

Based on previous literature and on exploratory analyses, the first adjusted model included gender, age at baseline (years), BMI (kg/m<sup>2</sup>), physical activity (irregular, <1 h walking/day,  $\geq 1$ h walking/day), tobacco status (never, former, current), education level (primary, secondary or university level), energy intake (Kcal/day) and alcohol consumption (g/day). In a second model, we also accounted for energy-adjusted saturated FA, energy-adjusted n-6 FA, fruit and vegetable consumption, hypertension, mellitus baseline diabetes and hypercholesterolemia and stroke and coronary heart diseases history. We performed a final model adjusted for depressive symptoms (using CES-D scale score).

Additional adjustments for cholesterol intake and vitamin E intake were also done. As they did not substantially modify the findings, these factors were not considered in the final model.

The supplementation group (intervention versus placebo) during the SU.VI.MAX trial (1994-2002) was not related to any markers of cognitive performances, assessed in the SU.VI.MAX 2 study. This cofactor was therefore not taken into account in the analyses.

All statistical analyses were performed using SAS software (version 9.1, SAS Institute Inc, Cary, NC, USA).

#### Results

A total of the 1,772 men and 1,522 women were retained for the present analysis (table 1).

Women reported stronger depressive symptoms, but had a better score on the MMSE and 5-word test than men.

Table 2 shows the association between cognitive function and intake of fish and related fatty acids. We did not observed significant association between poor scores on the MMSE and 5-word cognitive tests and intake of fish and related fatty acids. Nevertheless, subjects with high intake in total n-3 fatty acids showed less frequently a poor score on MMSE but the association was not significant.

Table 3 shows the association between self-administered cognitive difficulties and intake of fish and related fatty acids.

A poor score on the McNair CDS was negatively associated with increasing intake of EPA, DHA and long-chain n-3 FA (model 2). High consumption of fish was also associated with less frequent cognitive complaints but the association was only borderline significant after adjustment for depressive symptoms.

Table 1Characteristics (mean  $\pm$  SD or %) of men (N = 1,772) andwomen (N = 1,522) in the SU.VI.MAX 2 study, 2007-2009

	Men	Women	<b>P</b> <sup>1</sup>
N	1,772	1,522	
Age at clinical exam (years)	$64.7 \pm 4.7$	$63.7 \pm 4.6$	< 0.0001
Body mass index $(kg/m^2)$ (baseline)	$24.9 \pm 2.7$	$22.9 \pm 3.1$	< 0.0001
Intervention group during the trial phase	53.72	52.96	0.66
Hypertension (13.5% missing values) (baseline)		24.79	< 0.0001
Diabetes Mellitus (baseline)	5.81	2.56	< 0.0001
Hypercholesterolemia (baseline)	34.99	31.41	0.03
Physical activity (baseline)	01.77	01111	0.00
Irregular	23.31	23.32	< 0.0001
<1 h walking/d	23.14	36.14	10.0001
$\geq 1$ h walking/d	53.56	40.54	
Smoking status(baseline)			
Non-smoker	38.09	64.72	< 0.0001
Former smoker	50.68	25.56	
Current smoker	11.23	9.72	
Education level(baseline)			
Primary school	22.91	20.57	0.0002
High school	36.46	43.5	
University or equivalent	40.63	35.94	
Cognitive markers and CES-D			
McNair CDS (self-reported) (0-148, 0 is better)	29.2 ± 15.6	$30.3 \pm 15.8$	0.05
MMSE (0-30, 30 is better)	$28.56 \pm 1.44$	$28.63 \pm 1.46$	0.04
5-words (0-20, 20 is better)	$18.9 \pm 1.4$	$19.3 \pm 1.2$	< 0.0001
CES-D scale score (0-60, 0 is better)	$7.2 \pm 6.5$	$10.2 \pm 8.0$	< 0.0001
Intake (baseline)			
Energy <sup>2</sup> (Kcal/d)	$2316.6 \pm 506.0$	$1766.5 \pm 428.6$	< 0.0001
Ethanol (g/d)	$28.9 \pm 22.7$	$11.5 \pm 13.1$	< 0.0001
Carbohydrates <sup>3</sup>	$42.2 \pm 6.1$	$41.8 \pm 5.6$	0.02
Lipids <sup>3</sup>	$40.0 \pm 5.0$	$40.3 \pm 4.8$	0.05
Proteins <sup>3</sup>	$17.8 \pm 2.6$	$17.9 \pm 2.7$	0.40
Fish and seafood (g/d)	$51.3 \pm 35.8$	$42.3 \pm 29.8$	< 0.0001
EPA <sup>4</sup> (g/d)	$0.15 \pm 0.13$	$0.15 \pm 0.10$	0.33
DHA <sup>4</sup> (g/d)	$0.28 \pm 0.23$	$0.28 \pm 0.18$	0.18
Long-chain n-3 fatty acids4 (g/d)	$0.50 \pm 0.38$	$0.49 \pm 0.31$	0.47
Total n-3 fatty acids <sup>4</sup> (g/d)	$1.37 \pm 0.46$	$1.38 \pm 0.37$	0.01

EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; 1. P of chi-square test for categorical variables and of Wilcoxon-Mann-Whitney test for continuous variables; 2. Excluding energy from alcohol; 3. Values are percentage of total daily energy intake (without alcohol); 4. Energy-adjusted intake using residual (see methods section)

#### Discussion

In a large population-based study of French elderly, we observed that subjects with high intake of long-chain n-3 fatty acids at the onset of the study less frequently had a poor score on the McNair CDS evaluating cognitive difficulties, assessed 13 years later.

To our knowledge, no other studies have evaluated a potential link between diet and cognitive difficulties using a self-administered scale, which may be considered as an early indicator of cognitive impairment (33).

After accounting for depressive symptoms, results were partly attenuated but remained significant. This attenuation is not surprising. Indeed, McNair CDS and depression have been previously associated (25). In addition, n-3 PUFA are suspected to be associated with depression or mood despite a lack of consistent findings in epidemiological and clinical trials (34, 35).

# OMEGA-3 FATTY ACIDS, FISH AND COGNITION

# Table 2

# Adjusted OR (95%CI) for poor score on cognitive test across gender-specific quartile of intake of fish and related fatty acids assessed 13 years before

Global cognitive test (poor<27)		Q1	Q2	Q3	Q4	<b>P</b> <sup>1</sup>
EPA <sup>2</sup>	Model 1 <sup>3</sup>	1 [-]	1.08 [0.77-1.52]	0.84 [0.59-1.19]	0.98 [0.69-1.39]	0.57
	Model 24	1[-]	1.09 [0.78-1.53]	0.85 [0.60-1.22]	0.98 [0.69-1.39]	0.58
	Model 35	1[-]	1.11 [0.79-1.57]	0.82 [0.57-1.18]	0.96 [0.68-1.37]	0.47
DHA <sup>2</sup>	Model 1 <sup>3</sup>	1[-]	0.85 [0.61-1.20]	0.91 [0.65-1.28]	0.87 [0.62-1.23]	0.52
	Model 24	1[-]	0.86 [0.61-1.22]	0.93 [0.66-1.31]	0.87 [0.62-1.23]	0.55
	Model 35	1 [-]	0.87 [0.62-1.23]	0.89 [0.63-1.26]	0.85 [0.60-1.21]	0.41
Long-chain n-3 fatty acids <sup>2</sup>	Model 1 <sup>3</sup>	1 [-]	0.96 [0.68-1.34]	0.88 [0.62-1.24]	0.88 [0.62-1.24]	0.40
	Model 24	1[-]	0.97 [0.69-1.36]	0.89 [0.63-1.27]	0.88 [0.62-1.25]	0.41
	Model 35	1[-]	0.98 [0.70-1.39]	0.86 [0.60-1.22]	0.86 [0.61-1.23]	0.31
Total n-3 fatty acids <sup>2</sup>	Model 13	1[-]	0.95 [0.68-1.32]	0.89 [0.63-1.25]	0.79 [0.56-1.12]	0.18
	Model 24	1 [-]	0.97 [0.69-1.36]	0.92 [0.65-1.31]	0.79 [0.55-1.14]	0.21
	Model 35	1 [-]	0.95 [0.67-1.34]	0.91 [0.64-1.30]	0.75 [0.52-1.09]	0.14
Fish	Model 13	1[-]	1.10 [0.78-1.53]	0.98 [0.69-1.39]	0.84 [0.59-1.21]	0.29
	Model 24	1 [-]	1.13 [0.80-1.58]	0.99 [0.70-1.41]	0.83 [0.58-1.20]	0.26
	Model 3 <sup>5</sup>	1 [-]	1.10 [0.79-1.53]	0.97 [0.68-1.37]	0.85 [0.60-1.21]	0.29
Verbal Memory (poor<18)		Q1	Q2	Q3	Q4	<b>P</b> <sup>1</sup>
EPA <sup>2</sup>	Model 13	1[-]	0.78 [0.55-1.10]	1.00 [0.72-1.40]	1.00 [0.72-1.40]	0.63
	Model 24	1[-]	0.78 [0.55-1.11]	1.01 [0.72-1.41]	1.01 [0.72-1.41]	0.61
	Model 35	1[-]	0.79 [0.55-1.13]	0.97 [0.69-1.36]	1.01 [0.72-1.42]	0.67
DHA <sup>2</sup>	Model 1 <sup>3</sup>	1 [-]	0.89 [0.63-1.27]	1.02 [0.72-1.43]	1.13 [0.81-1.57]	0.36
	Model 24	1[-]	0.87 [0.61-1.23]	0.99 [0.71-1.40]	1.13 [0.80-1.57]	0.36
	Model 35	1 [-]	0.87 [0.61-1.23]	0.94 [0.66-1.33]	1.13 [0.81-1.59]	0.39
Long-chain n-3 fatty acids <sup>2</sup>	Model 1 <sup>3</sup>	1[-]	0.75 [0.53-1.07]	0.89 [0.63-1.24]	1.01 [0.73-1.40]	0.73
	Model 24	1[-]	0.75 [0.53-1.07]	0.88 [0.63-1.24]	1.02 [0.73-1.42]	0.70
	Model 1 <sup>3</sup>	1 [-]	0.76 [0.53-1.07]	0.84 [0.60-1.19]	1.02 [0.73-1.41]	0.77
Total n-3 fatty acids <sup>2</sup>	Model 13	1[-]	0.95 [0.68-1.33]	0.82 [0.58-1.16]	1.06 [0.76-1.47]	0.94
	Model 24	1[-]	0.93 [0.66-1.31]	0.79 [0.55-1.13]	1.03 [0.73-1.46]	0.94
	Model 35	1[-]	0.89 [0.63-1.26]	0.77 [0.54-1.11]	1.03 [0.72-1.46]	0.97
Fish	Model 1 <sup>3</sup>	1[-]	0.76 [0.54-1.08]	0.92 [0.66-1.29]	1.10 [0.79-1.54]	0.38
	Model 24	1[-]	0.78 [0.55-1.11]	0.92 [0.65-1.29]	1.09 [0.78-1.52]	0.45
	Model 35	1[-]	0.76 [0.53-1.07]	0.92 [0.66-1.29]	1.09 [0.78-1.51]	0.41

EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; 1. P for trend (all such values); 2. Energy-adjusted intake using residual (see methods section); 3. Model 1: adjusted for gender, age, BMI, physical activity, tobacco status, education, energy intake, alcohol; 4. Model 2: model 1 + baseline saturated fatty acids intake, n-6 fatty acids intake and fruit and vegetables consumption, baseline diabetes mellitus, hypercholesterolemia and hypertension and stroke and coronary heart diseases history; 5. Model 3: model 2 + CES-D scale score

# Table 3

# Adjusted OR (95%CI) for self-reported cognitive difficulties across gender-specific quartile of intake of fish and related fatty acids assessed 13 years before

Cognitive difficulties (poor>39)		Q1	Q2	Q3	Q4	$\mathbf{P}^1$
EPA <sup>2</sup>	Model 1 <sup>3</sup>	1 [-]	0.88 [0.70-1.10]	0.94 [0.75-1.18]	0.69 [0.55-0.88]	0.01
	Model 24	1 [-]	0.89 [0.71-1.12]	0.96 [0.76-1.20]	0.69 [0.55-0.87]	0.01
	Model 35	1 [-]	0.93 [0.73-1.19]	1.02 [0.80-1.29]	0.74 [0.58-0.95]	0.05
DHA <sup>2</sup>	Model 1 <sup>3</sup>	1 [-]	1.00 [0.80-1.26]	0.84 [0.67-1.05]	0.76 [0.60-0.96]	0.01
	Model 24	1 [-]	1.01 [0.81-1.27]	0.84 [0.67-1.06]	0.75 [0.60-0.95]	0.01
	Model 35	1 [-]	1.09 [0.86-1.39]	0.92 [0.72-1.17]	0.81 [0.63-1.03]	0.04
Long-chain n-3 fatty acids <sup>2</sup>	Model 1 <sup>3</sup>	1 [-]	0.84 [0.67-1.05]	0.86 [0.68-1.08]	0.68 [0.54-0.85]	0.002
	Model 24	1 [-]	0.86 [0.68-1.08]	0.87 [0.70-1.10]	0.68 [0.53-0.85]	0.002
	Model 35	1 [-]	0.88 [0.69-1.12]	0.96 [0.75-1.21]	0.72 [0.56-0.92]	0.02
Total n-3 fatty acids <sup>2</sup>	Model 1 <sup>3</sup>	1 [-]	1.04 [0.83-1.30]	0.89 [0.71-1.12]	0.81 [0.64-1.03]	0.04
	Model 24	1 [-]	1.01 [0.80-1.27]	0.85 [0.67-1.08]	0.75 [0.59-0.96]	0.01
	Model 35	1 [-]	1.09 [0.85-1.39]	0.91 [0.71-1.17]	0.80 [0.62-1.03]	0.04
Fish	Model 1 <sup>3</sup>	1 [-]	0.88 [0.70-1.11]	0.93 [0.74-1.17]	0.79 [0.62-1.00]	0.08
	Model 24	1 [-]	0.95 [0.75-1.21]	0.94 [0.73-1.19]	0.85 [0.66-1.09]	0.20
	Model 3 <sup>5</sup>	1 [-]	0.89 [0.70-1.11]	0.94 [0.75-1.18]	0.80 [0.63-1.01]	0.10

EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid; 1. P for trend (all such values); 2. Energy-adjusted intake using residual (see methods section); 3. Model 1: adjusted for gender, age, BMI, physical activity, tobacco status, education, energy intake, alcohol; 4. Model 2: model 1 + baseline saturated fatty acids intake, n-6 fatty acids intake and fruit and vegetables consumption, baseline diabetes mellitus, hypercholesterolemia and hypertension and stroke and coronary heart diseases history; 5. Model 2: model 2 + CES-D score

# JNHA: CLINICAL NEUROSCIENCES

In our study, we observed only a trend towards an association between poor score on MMSE and total n-3 fatty acids while a recent study observed a lower 5-year cognitive decline (assessed through a decrease in the MMSE score) among 70-89-year-old subjects having a high intake of EPA+DHA or fish (20). The absence of significant association between clinical cognitive tests and intakes of fish and n-3 FA may be due to a lack of power resulting from a reduced variability for cognitive performances evaluated through tests subjected to a ceiling effect. The MMSE has proven to be a reliable and valid indicator of cognitive impairment (36) but dietary factors may be associated with small effects on cognitive impairment, which may not be detected with the MMSE especially in a relatively young population with preserved cognitive function. In addition, it had previously been reported that, although variability between subjects is substantial, intake in long-chain n-3 FA in the SU.VI.MAX population is relatively high compared to that of other countries (1). If only very low intakes of n-3 FA are related to cognitive impairment, then it is possible that we would have been unable to detect such an effect because of the low proportion of the population presenting a very low intake. Evaluations of the relationship between cognitive performances or decline and intake of fish and n-3 FA have become increasingly frequent over the last few years. In observational studies, fish consumption has been relatively regularly associated with risk of dementia (7-10), cognitive impairment (14, 15, 19) and decline (17, 19, 20), apart from three studies (11, 12, 16). In contrast, findings on long-chain n-3 FA intake have been less consistent, as some prospective and cross-sectional studies found an association with dementia (7), cognitive decline (20) and cognitive impairment (14), while other prospective studies did not find such an association (12, 17, 19). In addition, the hypothesis of an association between cognition and intake of long-chain n-3 FA was strengthened by findings from studies focusing on plasma or erythrocyte concentrations (37-39), although one recently published study on erythrocyte membrane concentration did not observe this association (40). Disparities between these findings may be at least partly attributed to differences in study design (e.g. age of subjects, follow-up duration), the types of tests performed (e.g. specific or global cognitive test, self-administered or clinical exam) and the quality of dietary assessment, especially regarding food composition tables.

Some limitations in our study have to be emphasized. First, a lack of power may occur resulting from limited variability for cognitive performances as explained above. Second, generalizability of our findings may be discussed as our cohort was based on healthy volunteers participating initially in a nutritional intervention study who generally had a higher education level and occupational status, along with a healthier diet, than the general population (22). Third, there is a lack of cognitive evaluation assessment at baseline preventing us from evaluating cognitive decline. However, when participants were asked to report memory difficulties and attention trouble at

baseline, we observed no differences in dietary intakes according to their answers.

The prospective design of the current study, where diet was assessed several years before the assessment of cognitive functions, is an important strength. In addition, diet assessment through repeated 24 h records led to obtaining comprehensive and accurate dietary data, especially for n–3 FA intake. Fish consumption and long-chain n-3 FA intake may be a marker of a healthy diet (41), also characterized by high consumption of fruit and vegetables and thus high intake of antioxidants or folates, which may confound potential associations (6). Although we cannot exclude the possibility that specific confounders were not taken into account, a wide variety of cofactors, including diet and vascular factors, were assessed during the survey follow-up, thereby accounting for multiple confounding factors.

#### Conclusion

In conclusion, our study provides support that cognitive complaints may be less frequent among the elderly who had a high intake of long-chain n-3 fatty acids and fish consumption, even after adjustment for other markers of healthy lifestyle and depressive symptoms. As memory complaints may be an early sign of cognitive impairment, nutritional recommendations regarding long-chain n-3 fatty acids may help to prevent agedrelated cognitive decline.

# Appendix 1

# Members (City) of the Research SU.VI.MAX 2 Study Group

Luc Vogt (Agen); Michèle Escande (Allauch); Jean-Marie Sérot (Amiens); Emmanuel Vasseur (Angers); Matthieu Debray (Annecy); Chantal Hussonnois (Auxerre); Martine Iehl-Robert (Besançon); Myriam le Sommer (Bordeaux); Thierry Boge (Bourg en Bresse); Josiane Rajaonarivo (Bourges); Jean Jouseau (Bourges); Monique Frison (Brest); Armelle Gentric (Brest); Fabienne Leenaert (Caen); Bernard Bascou (Carcassonne); Jean-Paul Lemaire (Cavaillon); Nathalie Baptiste (Champcueil); Marie-France Maugourd (Champcueil); Anne Gibelain (Chartres); Roland Lopitaux (Clermont-Ferrand); Jacques Hild (Colmar); Henri Nachar (Avignon); Géraldine Soulié (Dax); Francine Clémenti (Dax); Patrick Friocourt (Blois); Alain Sagnier (Chambéry); Philippe Schiano (Hyères); Andréa Collet (Port-Louis Riantec); Dominique Richard (Dijon); Françoise Zandi (Gradignan); Pascal Couturier (Grenoble); Agathe Raynaud-Simon (Ivrv): Pierre Lermite (La Roche sur Yon): Michel Alix (La Rochelle): Emmanuel Alix (Le Mans); François Puisieux (Lille); Cédric Gaxatte (Lille); Thierry Dantoine (Limoges); Pierre livet (Lyon); Gilles Albrand (Lyon); Pierre Haond (Lyon); Pascal Ménecier (Macon); François Pinoche (Malestroit); Sylvie Bonin Guillaume (Marseille); Marc Heim (Marseille); André Wang (Metz); Claude Jeandel (Montpellier); Yves Passadori (Mulhouse); Athanase Benetos (Nancy); Catherine Couturier (Nantes); Gilles Berrut (Nantes); Sylvie Sacher-Huvelin (Nantes); Henri Patouraux (Nevers); Patrice Brocker (Nice); Olivier Guérin (Nice); Denise Strubel (Nîmes); Florence Dupriez (Orléans); Jean-Bernard Gauvain (Orléans); Yves Wolmark (Paris); Olivier Hanon (Paris); Bernard Cassou (Paris); Philippe Déjardin (Paris, Troyes); François de la Fournière (Pau); Frédéric Woné (Périgueux); Claudine Buj-Hardy (Perpignan); Marc Paccalin (Poitiers); Bertrand Placines (Pontacq-Nay); Jean-Luc Novella (Reims); Pierre Jouanny (Rennes); Florence Martin (Rodez, Toulouse); Philippe Chassagne (Rouen); Isabelle Landrin (Rouen); Chantal Girtanner (Saint-Etienne); Régis Gonthier (Saint-Etienne); Claudie Troadec (Saint-Brieuc); Christophe Dourthe (Saintes); Eric Bonnin (Saintes); Jean-Paul Marot

# OMEGA-3 FATTY ACIDS, FISH AND COGNITION

(Saint-Nazaire); Sylvie Rossignol (Sens); Georges Sebbane (Sevran); Pierre-Yves Cornu (Sevran); Jean-Jacques Monsuez (Sevran); Isabelle Périllat (Sevran); Robert Ratiney (Sevran); Georges Kaltenbach (Strasbourg); Yves Rolland (Toulouse); Thierry Constans (Tours); Gisèle Coz (Tréguier); Monique Ferry (Valence); Jean Pierre Aquino (Versailles); Odile Cézard (Voiron).

Acknowledgments: We thank all scientists, dieticians, technicians and assistants who helped carry out the SU.VI.MAX 2 study. We especially thank Nathalie Arnault (statistician) who coordinated data management, Rachida Mehroug (assistant) for logistic aspects, Paul Flanzi (data entry tool development) and Gwenael Monot (computer scientist), who coordinated computer aspects. We also thank Jerri Bram for revising and editing the manuscript. This work was granted by ANR (n°ANR-05-PNRA-010), DGS (Ministry of Health) and supported by Médéric, Sodexo, Ipsen, MGEN and Pierre Fabre.

Financial disclosure: None of the authors had any financial interest or support for this paper.

# References

- Astorg P, Arnault N, Czernichow S, Noisette N, Galan P, Hercberg S. Dietary intakes and food sources of n-6 and n-3 PUFA in French adult men and women. Lipids 2004; 39(6):527-535.
- Hercberg S, Chat-Yung S, Chaulia M. The French National Nutrition and Health Program: 2001-2006-2010. Int J Public Health 2008; 53(2):68-77.
- Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 2006; 83(6 Suppl):1505S-1519S.
- Dangour AD, Uauy R. N-3 long-chain polyunsaturated fatty acids for optimal function during brain development and ageing. Asia Pac J Clin Nutr 2008; 17 Suppl 1:185-188.
- Issa AM, Mojica WA, Morton SC et al. The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: a systematic review. Dement Geriatr Cogn Disord 2006; 21(2):88-96.
- Gillette GS, Abellan vK, Andrieu S et al. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging 2007; 11(2):132-152.
- Morris MC, Evans DA, Bienias JL et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60(7):940-946.
- Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997; 42(5):776-782.
- Barberger-Gateau P, Raffaitin C, Letenneur L et al. Dietary patterns and risk of dementia: the Three-City cohort study. Neurology 2007; 69(20):1921-1930.
- Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ 2002; 325(7370):932-933.
- 11. Engelhart MJ, Geerlings MI, Ruitenberg A et al. Diet and risk of dementia: Does fat matter?: The Rotterdam Study. Neurology 2002; 59(12):1915-1921.
- Devore EE, Grodstein F, van Rooij FJ et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr 2009; 90(1):170-176.
- Vercambre MN, Boutron-Ruault MC, Ritchie K, Clavel-Chapelon F, Berr C. Longterm association of food and nutrient intakes with cognitive and functional decline: a 13-year follow-up study of elderly French women. Br J Nutr 2009; 102(3):419-427.
- Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 2004; 62(2):275-280.
- Nurk E, Drevon CA, Refsum H et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr 2007; 86(5):1470-1478.
- Rahman A, Sawyer BP, Allman RM, Zamrini E. Dietary factors and cognitive impairment in community-dwelling elderly. J Nutr Health Aging 2007; 11(1):49-54.
- Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005; 62(12):1849-1853.
- Laurin D, Verreault R, Lindsay J, Dewailly E, Holub BJ. Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimers Dis 2003; 5(4):315-322.

- Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 1997; 145(1):33-41.
- van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007; 85(4):1142-1147.
- Hercberg S, Galan P, Preziosi P et al. Background and rationale behind the SU.VI.MAX Study, a prevention trial using nutritional doses of a combination of antioxidant vitamins and minerals to reduce cardiovascular diseases and cancers. SUpplementation en VItamines et Mineraux AntioXydants Study. Int J Vitam Nutr Res 1998; 68(1):3-20.
- 22. Hercberg S, Galan P, Preziosi P et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164(21):2335-2342.
- Le Moullec N, Deheeger M, Preziosi P et al. Validation du manuel photos utilisé pour l'enquête alimentaire de l'étude SU.VI.MAX. Cahier de Nutrition et de Diététique 1996; 31(3):158-164.
- 24. Radloff L. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas 1977; 1:385-401.
- Derouesné C, Dealberto M.J., Boyer P et al. Empirical evaluation of the l"Cognitive Difficulties Scale" for assessment of memory complaints in general practice: A study of 1628 cognitively normal subjects aged 45-75 years. Int J Geriatr Psychiatry 1993; 8(7):599-607.
- Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3):189-198.
- Dubois B, Touchon J, Portet F, Ousset PJ, Vellas B, Michel B. ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. Presse Med 2002; 31(36):1696-1699.
- Fox-Wasylyshyn SM, El Masri MM. Handling missing data in self-report measures. Res Nurs Health 2005; 28(6):488-495.
- Hercberg S (coordinator). Table de composition SU.VI.MAX des aliments. Paris: Les éditions INSERM/Economica, 182 pages, 2005.
- Willett WC. Nutritional Epidemiology. 2nd ed. New York, NY: Oxford University Press: 1998.
- Croisile B, Astier JL, Beaumont C. [Standardization of the 5-word test in a group of 191 normal subjects aged 50 to 90 years]. Rev Neurol (Paris) 2007; 163(3):323-333.
- Cowppli-Bony P, Fabrigoule C, Letenneur L et al. [Validity of the five-word screening test for Alzheimer's disease in a population based study]. Rev Neurol (Paris) 2005; 161(12 Pt 1):1205-1212.
- Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 2000; 15(11):983-991.
- 34. Appleton KM, Rogers PJ, Ness AR. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? A review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev 2008; 21(1):13-41.
- Sontrop J, Campbell MK. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev Med 2006; 42(1):4-13.
- Siu AL. Screening for dementia and investigating its causes. Ann Intern Med 1991; 115(2):122-132.
- Heude B, Ducimetiere P, Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes--The EVA Study. Am J Clin Nutr 2003; 77(4):803-808.
- Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2007; 85(4):1103-1111.
- Dullemeijer C, Durga J, Brouwer IA et al. n 3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr 2007; 86(5):1479-1485.
- Kroger E, Verreault R, Carmichael PH et al. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr 2009; 90(1):184-192.
- Barberger-Gateau P, Jutand MA, Letenneur L, Larrieu S, Tavernier B, Berr C. Correlates of regular fish consumption in French elderly community dwellers: data from the Three-City study. Eur J Clin Nutr 2005.